相关临床试验
34
22 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
22
64.7%
已完成
4
11.8%
招募中
7
20.6%
撤回
1
2.9%
暂无批准数据
- Teitur Trophics reported positive Phase I results for TT-P34, a first-in-class neuroprotective peptide tested in 55 healthy volunteers and 12 patients with early-stage Parkinson's disease. - Once-weekly subcutaneous dosing was well tolerated at all levels tested with no dose-limiting findings, and pharmacokinetics confirmed dose-dependent exposure in the brain and central nervous system. - Early biomarker signals were consistent with lysosomal pathway engagement, supporting a planned Phase II trial in Parkinson's disease patients in 2027. - Teitur is now raising a Series B round to fund the Phase II study, which will explore TT-P34's therapeutic benefit and disease-modifying potential.
- ResearchAndMarkets.com has released a comprehensive report analyzing licensing deals in biotechnology from 2020 to 2025, providing insights into deal trends and structures. - The report covers hundreds of companies including major players like AbbVie, ACADIA Pharmaceuticals, and emerging biotech firms across various therapeutic areas and technology types. - Key features include financial terms analysis covering upfront payments, milestones, and royalties, plus access to actual contract documents for due diligence purposes. - The analysis enables benchmarking of transaction values and identification of the most active dealmakers in the biotechnology licensing landscape.
- Commit Biologics has established a Scientific Advisory Board co-chaired by antibody expert Janine Schuurman and CEO Mikkel Wandahl Pedersen to guide development of its BiCE™ complement activation platform. - The board includes five industry veterans with expertise in molecular biology, immunology, and antibody research, including former executives from Genmab, Regeneron, and Novo Nordisk. - The BiCE™ technology platform aims to harness the largely untapped complement system to selectively kill target cells in autoimmune diseases and cancer through enhanced C1q engagement. - This strategic move positions Commit to accelerate development of first-in-class complement engager therapeutics by leveraging decades of combined industry experience from the advisory members.
- The European Respiratory Society Congress 2024 highlighted key ethical principles for AI integration in healthcare, including patient autonomy, beneficence, and the need for explainable AI systems. - Studies revealed significant accuracy concerns in AI healthcare applications, with one system missing 67% of sepsis cases and showing bias in diagnosing conditions across different demographic groups. - AI's environmental impact raises sustainability concerns, with healthcare AI technologies projected to consume as much power as Japan by 2026, prompting discussions on balancing innovation with ecological responsibility.
